Search | Clinical Trials Finder

Conditions: Major Depressive Disorder
Interventions: Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 41
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more

Conditions: Major Depression Disorder
Interventions: Adjunct brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 65 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Arcadia, California • Miami, Florida • Orlando, Florida + 9 more

Conditions: Major Depressive Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more

Conditions: Inflammatory Bowel Diseases
Interventions: Duloxetine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 24 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Treatment Resistant Depression
Interventions: ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR; Drug
Lead sponsor: Alar Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 4
States / cities: Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Garden Grove, California • National City, California • Oceanside, California + 34 more

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Antidepressant Therapy (ADT); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 88
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more

Conditions: Methamphetamine Use Disorder
Interventions: Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine; Drug
Lead sponsor: Craig Rush; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Major Depressive Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate ), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 47
States / cities: Birmingham, Alabama • Carson, California • Irvine, California + 42 more

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Rafael, California + 7 more

Conditions: Treatment-resistant Depression
Interventions: Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 83
States / cities: Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more

Conditions: Major Depressive Disorder
Interventions: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 36
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Major Depressive Disorder
Interventions: TC-5214, Duloxetine, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 25
States / cities: Beverly Hills, California • Chino, California • Garden Grove, California + 22 more

Conditions: Treatment Resistant Major Depressive Disorder
Interventions: Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more

Conditions: Depression
Interventions: duloxetine, fluoxetine, citalopram, paroxetine, sertraline; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 61
States / cities: Carson, California • Irvine, California • San Diego, California + 58 more

Conditions: Depressive Disorder, Major
Interventions: SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 51
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more

Conditions: Generalized Anxiety Disorder
Interventions: Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 36
States / cities: Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more

Conditions: Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions: Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication; Device · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more

Search by objective public record fields.

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Duloxetine in Inflammatory Bowel Diseases

Multiple Ascending Dose Phase 1 Study of ALA-3000

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression